OncoDaily Pulse

Aug 27, 2025, 16:00

Raquibul Hannan: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register via the link.

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Raquibul Hannan

Dr. Raquibul Hannan is a Professor of Radiation Oncology and Chief of the Genitourinary Radiation Oncology Service at UT Southwestern Medical Center in Dallas, Texas. He is recognized for his expertise in radiation treatment of genitourinary cancers, including kidney cancer, with a focus on integrating advanced radiation techniques and immunotherapy.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Hannan will present on “Radiation Approaches for Oligoprogressive Disease”.
His presentation will cover:

Innovative radiation strategies targeting oligoprogressive renal cell carcinoma and their clinical applications.
The role of stereotactic body radiation therapy (SBRT) and other advanced modalities in managing disease progression.
Insights into combining radiation with systemic therapies to optimize patient outcomes.
Multidisciplinary approaches that enhance comprehensive care for patients with advanced RCC.

Drawing upon his extensive clinical experience and research, Dr. Hannan emphasizes tailored radiation approaches that maximize efficacy while minimizing toxicity, aiming to improve the quality of life and survival of patients with advanced renal cancers.

Global Voices in Renal Oncology (VIRO) 2025

cancer Global Voices in Renal Oncology Oligoprogressive Disease OncoDaily Oncology RCC renal cell carcinoma stereotactic body radiation therapy UT Southwestern Medical Center VIRO 2025

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

Simon Mooijaart: Patient Perspectives on Antithrombotic Therapy in Advanced Cancer

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?